PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 142 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,874,596 | -47.0% | 232,290 | -12.2% | 0.00% | -100.0% |
| Q2 2023 | $7,311,207 | +199.5% | 264,707 | +149.4% | 0.00% | – |
| Q1 2023 | $2,441,000 | +73690.8% | 106,133 | -65.0% | 0.00% | – |
| Q4 2022 | $3,308 | -99.8% | 303,162 | +72.7% | 0.00% | – |
| Q3 2022 | $1,480,000 | +55.1% | 175,559 | +45.7% | 0.00% | – |
| Q2 2022 | $954,000 | -41.8% | 120,495 | +74.2% | 0.00% | – |
| Q1 2022 | $1,639,000 | -89.0% | 69,183 | -84.1% | 0.00% | -100.0% |
| Q4 2021 | $14,926,000 | +96.5% | 436,453 | +1.8% | 0.00% | +100.0% |
| Q3 2021 | $7,597,000 | -60.9% | 428,695 | -1.1% | 0.00% | -50.0% |
| Q2 2021 | $19,453,000 | +28.4% | 433,428 | -25.9% | 0.00% | 0.0% |
| Q1 2021 | $15,149,000 | +6.9% | 584,897 | -16.8% | 0.00% | 0.0% |
| Q4 2020 | $14,172,000 | -10.8% | 703,007 | -10.4% | 0.00% | -33.3% |
| Q3 2020 | $15,891,000 | +7.4% | 784,718 | -6.3% | 0.00% | 0.0% |
| Q2 2020 | $14,797,000 | +137.4% | 837,864 | -5.1% | 0.00% | +200.0% |
| Q1 2020 | $6,234,000 | +242.2% | 883,013 | +241.6% | 0.00% | – |
| Q4 2019 | $1,822,000 | -46.2% | 258,467 | -8.4% | 0.00% | -100.0% |
| Q3 2019 | $3,389,000 | -49.4% | 282,159 | -49.5% | 0.00% | 0.0% |
| Q2 2019 | $6,693,000 | +89.7% | 558,729 | +99.1% | 0.00% | 0.0% |
| Q1 2019 | $3,528,000 | +220.4% | 280,663 | +71.6% | 0.00% | – |
| Q4 2018 | $1,101,000 | -55.5% | 163,524 | -32.0% | 0.00% | – |
| Q3 2018 | $2,476,000 | +437.1% | 240,638 | +250.8% | 0.00% | – |
| Q2 2018 | $461,000 | +2205.0% | 68,591 | +2888.7% | 0.00% | – |
| Q1 2018 | $20,000 | -99.5% | 2,295 | -98.9% | 0.00% | -100.0% |
| Q4 2017 | $4,258,000 | +4335.4% | 204,759 | +2318.0% | 0.00% | – |
| Q2 2017 | $96,000 | -18.6% | 8,468 | -7.9% | 0.00% | – |
| Q1 2017 | $118,000 | -49.4% | 9,197 | -13.3% | 0.00% | – |
| Q4 2016 | $233,000 | +417.8% | 10,610 | +403.3% | 0.00% | – |
| Q3 2016 | $45,000 | – | 2,108 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $56,331,209 | 18.32% |
| Kynam Capital Management, LP | 1,375,000 | $31,625,000 | 4.08% |
| BVF INC/IL | 3,775,900 | $86,845,700 | 3.18% |
| Cormorant Asset Management, LP | 1,700,000 | $39,100 | 2.58% |
| RTW INVESTMENTS, LP | 4,600,799 | $105,818,377 | 2.20% |
| Ghost Tree Capital, LLC | 225,000 | $5,175,000 | 1.53% |
| 683 Capital Management, LLC | 791,000 | $18,193,000 | 1.36% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 105,486 | $2,426,178 | 1.00% |